



Citation for published version:

Jolly, P, Formisano, N & Estrela, P 2015, 'DNA Aptamer-based detection of prostate cancer', *Chemical Papers*, vol. 69, no. 1, pp. 77-89. <https://doi.org/10.1515/chempap-2015-0025>

DOI:

[10.1515/chempap-2015-0025](https://doi.org/10.1515/chempap-2015-0025)

Publication date:

2015

Document Version

Early version, also known as pre-print

[Link to publication](#)

University of Bath

Alternative formats

If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

DNA aptamer-based detection of prostate cancer

Pawan Jolly, Nello Formisano, Pedro Estrela

*Department of Electronic & Electrical Engineering, University of Bath, Bath BA2 7AY,
United Kingdom*

Corresponding author: Dr Pedro Estrela; P.Estrela@bath.ac.uk; Department of Electronic and Electrical Engineering, University of Bath, Claverton Down, Bath, BA2 7AY, United Kingdom

Received [Dates will be filled in by the Editorial office]

The use of aptamers in biosensing have gained considerable attention as an attractive alternative to antibodies because of their unique properties such as long term stability, cost effectiveness and tunability to various applications. Among various cancers, early diagnosis of prostate cancer (PCa) is one of the biggest concerns for ageing men worldwide. One of the most commonly used biomarker for PCa is prostate specific antigen (PSA), which can be found in elevated levels in patients with cancer. In this review, a presentation on the gradual transition of research from antibody-based to aptamer-based biosensors is presented specifically for PSA. A brief description on aptamer-based biosensing for other PCa biomarkers is also presented. Special attention is given to electrochemical methods as analytical techniques for development of simple, sensitive and cost effective biosensors. The review also focuses on different surface chemistries exploited for fabrication and their application with clinical samples. Utilization of aptamers provides a promising tool for development of point-of-care biosensors for early detection of prostate cancer. In the view of the unmatched upper hand of aptamers, future perspectives are also discussed, not only in the point of care format but also in other novel applications.

Keywords: DNA aptamer, biosensor, electrochemical detection, prostate specific antigen, prostate cancer, surface chemistry

34

35

36

Introduction

37

38 Prostate cancer (PCa) is a type of cancer that develops in the prostate gland, which is a
39 part of a male reproductive system. PCa is the most commonly diagnosed cancer amongst
40 men in Europe and the United States and is the second worldwide leading cause of morbidity.
41 It has been reported that PCa is predominant in older men above the age of 50 (Kirk, 1997;
42 Hoffman, 2011) and among black men (Stanford et al., 1999; Greenlee et al., 2000). It has
43 been also projected that PCa will be the most common cancer by 2030 in the UK (Greenlee et
44 al., 2000; Jeong et al., 2010).

45 Most of the PCa generate in the epithelium cells (Bostwick, 1989). As androgens
46 regulate cell division of the gland epithelium (Ross et al., 1998), these hormones are believed
47 to be the main cause of PCa. However, a study demonstrating a consistent correlation between
48 androgens and prostatic carcinogenesis has not yet been reported to date and the precise
49 causes that lead to PCa are still not well understood (Kufe et al., 2003).

50 PCa often develops very slowly and the lack of symptoms during the early stages of
51 the disease leads to a late diagnosis of the tumour. Moreover, if diagnosed at a late stage, no
52 effective treatments are currently available for its cure. In many cases PCa does not show any
53 clinical manifestation during the lifetime of a patient, who might die for non-related PCa
54 causes. However, for those patients that develop a more aggressive cancer form, PCa cells can
55 break away from a prostate tumour and metastasise. Since the prostate is well connected to
56 numerous lymph nodes, the spread is easy and some of the most common sites of PCa
57 metastatic process are bones (Chou & Simons, 1997).

58

59

60

Current detection methods

61

62 There is no solitary test for the diagnosis of PCa. Moreover, all the tests which are
63 used to diagnose have pros and cons which are usually discussed by the doctors with their
64 patients. The most commonly used methods for PCa detection are: digital rectal examination
65 (DRE), transrectal ultrasound (TRUS), biopsy and PSA blood test.

66 In DRE, a doctor inserts a gloved finger into the rectum and examines for bumps or
67 swelling of the prostate gland. It is an inexpensive method and can also detect PCa

68 irrespective of changes in the level of prostate specific antigen (PSA) in blood. Accuracy of
69 diagnosis can be increased when DRE is combined with PSA tests and biopsy results (Uzzo et
70 al., 1995; Basler & Thompson, 1998; Jeong et al., 2010). In comparison to DRE, in the TRUS
71 method an ultrasound probe is inserted into the rectum, emitting energy sound waves to image
72 the prostate gland. It is a very useful tool to understand pathology of tumours and in guiding
73 needle biopsies for sampling of tissue (Aus et al., 1996; Irani et al., 1997). For a biopsy, a
74 small section of the tissue is removed through the rectum using a needle and is
75 microscopically examined by pathologists. It requires a high number of samples from the
76 prostate making it a painful protocol. Not only the results from biopsies are controversial,
77 there is also a high risk of severe infections with subsequent biopsies (Jeong et al., 2010; Loeb
78 et al., 2013).

79 The most frequently used test for PCa screening is the quantification of levels of PSA
80 in blood. If PSA levels are higher than the cut off levels of 4 ng/ml, biopsy procedures are
81 considered (Catalona et al., 1991, Jeong et al., 2010; Savory et al., 2010). However, the levels
82 of PSA in blood in ageing men can also be raised due to other factors like benign prostatic
83 hyperplasia (BPH) and prostatitis, which could lead to an over-diagnosis in men (Carter et al.,
84 1992). Consequently, due to faulty diagnosis, patients undergo biopsy surgery making PSA
85 testing a controversial diagnostic tool. Due to these controversies with PSA testing, in May
86 2012 the US Preventative Services Task Force recommended against PSA screening in all
87 men. This emphasized the need for more reliable biomarkers for diagnosis of the disease
88 (Moyer, 2012).

89

90

91

Prostate specific antigen (PSA): a PCa biomarker

92

93 PSA belongs to the family of kallikrein proteins which are defined as serine proteases.
94 There are about 15 kallikrein family members that have been identified in humans. PSA is the
95 only kallikrein specific to prostate (hK3). Pancreatic renal kallikrein (hK1) and human
96 glandular kallikrein (hK2), which are androgen regulated, are also expressed in the prostate
97 (Balk et al., 2003).

98

99 PSA is synthesised in its inactive form: a 244 amino acid long protein called pro-PSA.
100 Pro-PSA is cleaved from the N terminus in the prostate by the hK2 enzyme leading to active
101 PSA which is a 237 amino acid long protein (Takayama et al., 1997). The active PSA is a
101 30 kDa protein which can be found in both serum and semen of men. PSA is present in semen

102 in the range of 0.5 - 2 mg/ml and its physiological role is to de-coagulate semen by breaking
103 down the proteins semenogelin I and II (Lilja et al., 1987; Lövgren et al., 1999). In prostate
104 cancer there is release of both active PSA and pro-PSA due to rupture of the basal membrane.
105 Moreover, internally cleaved forms of PSA (with no enzymatic activity) also enter the blood
106 stream but remain un-complexed and are taken into the free PSA (fPSA) count. However,
107 when active PSA enters the blood stream it becomes immediately complexed with protein
108 inhibitors. Most of the assays employing antibodies measure the total amount of PSA (tPSA)
109 (Takayama et al., 1997).

110 Many studies reported that PSA levels are directly proportional to the stage of the
111 cancer and to the volume of the tumour (Stamey et al., 1987; Grossklaus et al., 2002; Pinsky
112 et al., 2007; Lilja et al., 2008). PSA detection results are nowadays highly sensitive (Madu &
113 Lu, 2010) and reasonably inexpensive. Moreover PSA testing is a more accepted procedure
114 by patients compared to DRE and this has augmented the early detection of PCa (Balducci et
115 al., 1997). However, even though PSA testing induced a decrease in PCa mortality of 20% its
116 screening led to over-diagnosis and over-treatment (Andriole et al., 2009) of patients that
117 would have not been clinically affected by the tumour during their lifetime. Over diagnosis
118 can, in fact, lead to unnecessary treatments and increase the state of anxiety in patients.
119 Conversely, clinicians are not able nowadays to discriminate between a harmless or lethal
120 form of prostate cancer and so to decide whether the patient needs a treatment. Once a
121 prostate cancer has been definitively treated, PSA screening is the most reliable and fast
122 means that enable to detect a contingent recurrence of the tumour (Lilja et al., 2008).

123 With the shortcomings of the current tests for PCa, including PSA testing, there is a
124 concerted effort to look for alternatives. However, it would be a challenge to replace PSA
125 entirely due to its minimally invasive nature and low cost. Instead, there is a pressing need to
126 look for other biomarkers to complement PSA that can increase the specificity and sensitivity
127 of PCa screening and inform prognosis and treatment courses.

128 One path currently being looked at when a high level of PSA is detected in patients
129 with cancer, is to differentiate PSA into different forms namely free PSA (fPSA) and total
130 PSA (tPSA) and quantify them independently. One of the approaches is to measure the ratio
131 of free PSA to total PSA in the blood. It has been proven, in fact, that the levels of fPSA are
132 lower in patients with PCa than in patients with BPH (Christensson et al., 1993), which can
133 thus be an indication of the aggressiveness of the cancer. However, the method can cause
134 false negative results as the amount of fPSA can be higher in patients with larger prostate
135 volume (Stephan et al., 1997; Catalona et al., 1998). Nevertheless, the ratio of free to total

136 PSA when combined with the total PSA levels increases the confidence of the diagnosis
137 (Velonas et al., 2013).

138

139 ***Pro-PSA***

140 Several studies are also focused on the detection of a distinct form of free PSA, called
141 proenzyme PSA (pro-PSA). Pro-PSA is an enzymatically inactive precursor of PSA obtained
142 by co-translational removal of an amino-terminal leader. The N-terminal of pro-PSA can be
143 cleaved at various positions resulting in different forms of pro-PSA. Pro-PSA truncated
144 between the third and second amino acid is called [-2]pro-PSA and is believed to provide a
145 better discrimination between cancerous and benign form of prostate disorders (Mikolajczyk
146 et al., 2001; Mikolajczyk et al., 2004). Increased values of other forms of pro-PSA ([-5] and
147 [-7]) have also been associated to PCa. A truncated precursor form of prostate-specific
148 antigen is therefore a more specific serum marker of prostate cancer.

149

150 ***PSA density***

151 A better discrimination of BPH from PCa might be achieved by measuring the ratio of
152 PSA to prostate volume. However, this parameter called PSA density showed contradictory
153 evidence on the tumour aggressiveness and malignity (Stamey et al., 1987; Ohori et al.,
154 1995). Furthermore, in order to obtain prostate volume values, TRUS is required in addition
155 to the standard PSA test with a consequent discomfort for patients as well as an increase in
156 the cost and time required to perform the test. For these reasons PSA density has not been
157 extensively employed as a routine test for PCa.

158

159 ***PSA velocity and PSA doubling time***

160 PSA velocity refers to the rate of serum PSA increase over time while PSA double
161 time refers to the time required for a given PSA level to be doubled. As the previous PSA
162 derivatives, also PSA velocity can be used to distinguish a prostate cancer from a BPH (Carter
163 et al., 1992). Both PSA velocity and PSA double time are used to monitor the recurrence of
164 the tumour after treatment (D'Amico et al., 2004; D'Amico et al., 2005). Again, some studies
165 compared the responses from PSA velocity and PSA double time with biopsy results
166 demonstrating how these two PSA derivatives can fail the diagnosis (Melichar, 2012)

167

168 *Age-specific PSA reference ranges*

169 Since the level of PSA increases with the age of men, scientists studied this correlation
170 in order to obtain a median value of PSA for given ranges of age. By comparing the PSA
171 level with the median PSA for that patient's age (age-specific PSA) a better choice might
172 been taken before ordering biopsies (Loeb & Catalona, 2007).

173

174

175

Oligonucleotide Aptamers

176

177 In recent years, a range of assays for PSA detection such as electrochemical assays
178 (Okuno et al., 2007; Panini et al., 2008), enzyme linked immunosorbent assays (Acevedo et
179 al., 2002), cantilever assays (Wee et al., 2005), and chemiluminescent immunoassays
180 (Albrecht et al., 1994; Seto et al., 2001) have been developed. These assays are mostly based
181 on antibodies as recognition elements. One of the alternatives to antibodies is aptamers which
182 can offer several advantages with respect to the former. However, an enormous research is
183 being carried out to prove if antibodies can be replaced by aptamers to develop a real
184 biosensor for clinical applications. The scope of this review is to highlight the major
185 developments on PSA aptasensors and their potential to be used with real clinical blood
186 samples.


187 Oligonucleotide aptamers are single stranded DNA or RNA sequences that can bind to
188 a target molecule with high specificity and affinity. Aptamers had already been widely used in
189 drug delivery applications and are now being extensively studied as new emerging
190 bioreceptors for biosensors (termed aptasensors) (Hianik & Wang, 2009; Iliuk et al., 2011).
191 Aptamers have shown comparable or even stronger binding than antibodies towards a broad
192 range of targets (e.g. proteins, peptides, amino acids, drugs, whole cells, etc.), especially with
193 the development of novel selection technologies (Xiao et al., 2005). The high affinity of the
194 aptamers towards the target molecule is defined by their capability of undergoing
195 conformation changes upon the binding event (Hermann & Patel, 2000; Song et al., 2008;
196 Hianik & Wang, 2009). Although using aptamers have many added advantages over
197 antibodies, they still need careful consideration while fabricating a biosensor. For instance,
198 binding of an aptamer to protein might be affected by changing buffer conditions. Also, as
199 aptamers are oligonucleotide sequences, special care is needed as they are sensitive to DNase

200 and RNase activity. Furthermore, the k_d value of aptamers is often not as good as that for
 201 antibodies.

202 Aptamers are developed using an *in vitro* selection process based on Systematic
 203 Evolution of Ligands by EXponential enrichment (SELEX) (see fig. 1). Briefly, it consists of
 204 three steps that are repeated systematically in order to identify the oligonucleotide sequence
 205 that binds better to the target. The first step is called library generation, where a library
 206 consisting of random DNA or RNA sequences (usually 30-40 base-pairs long) flanked by the
 207 primer binding site are used. The library is then incubated with the target molecule.
 208 Thereafter, the target bound library is separated from unbound library. Finally, the target-
 209 bound library is amplified using polymerase chain reaction (PCR) to create a new library to be
 210 used in the next round. Aptamers binding and conformation characteristics are identified
 211 using various biological assays (Syed & Pervaiz, 2010; Liu et al., 2012).

212

213



214

215

216 **Fig. 1.** The general SELEX protocol. Starting with a random library followed by incubation
 217 with the target. Later the bound sequences are separated and further amplified for the
 218 next round of selection. Adapted from Song et al. (2008).

219

220

221 There has been an intense interest in understanding the in-depth of ligand-binding and
222 conformational properties of aptamers. Aptamers have many advantages over antibodies,
223 making them very important molecular tools for both diagnostics and therapeutics. For
224 instance, selection of aptamers is an *in vitro* process and they can be raised to a wide variety
225 of targets ranging from small molecules and toxins to large proteins and even whole cells.
226 Secondly, aptamers, once selected, can be synthesised with high purity and reproducibility.
227 Also, as compared to antibodies, aptamers are usually highly chemically stable. Furthermore,
228 they can undergo significant conformational changes in their structure upon binding with the
229 target – a feature which can be exploited for biosensing applications. This offers great
230 flexibility to design novel biosensors (Clark & Remcho, 2002; Tombelli et al., 2005; Willner
231 & Zayats, 2007; Mairal et al., 2008; Song et al., 2008; Liu et al., 2012).

232

233

234

PSA detection

235

236 PSA is currently detected in dedicated laboratory settings using automated analysers
237 running antibody-based assays which are generally expensive and time consuming (Lin & Ju,
238 2005; Healy et al., 2007). Cost effective, easy to use and possibly portable devices are
239 required in order to allow more powerful tools for early detection of prostate cancer. To date,
240 researchers have exploited several techniques for PSA detection such as optical (Besselink et
241 al., 2004; Huang et al., 2005; Cao & Sim, 2007), piezoelectric (Weeks et al., 2003; Wee et al.,
242 2005) and electrochemical (Sarkar et al., 2002; Fernández-Sánchez et al., 2004; Liu et al.,
243 2013).

244

245 Although label-free-based biosensors can provide many advantages, label-based
246 approaches are still intensively studied and can offer interesting features such as low limit of
247 detection due to amplification strategies. An interesting magnetic bead-based detection system
248 for PSA detection was developed by Zani et al. (2009): paramagnetic microparticles were
249 adsorbed on an array of screen-printed electrodes and PSA was sandwiched in between two
250 antibodies on the beads; the alkaline-phosphatase-labelled secondary antibody could be
251 detected with differential pulse voltammetry (DPV) to achieve a detection limit of 1.4 ng/ml.
252 A limit of detection as low as 0.5 pg/ml in undiluted serum samples was obtained by Mani et
253 al. (2010) by combining a multienzyme-labelled immunoassay with gold nanoparticles
254 sensing surface: in this case the secondary antibody was bound to micromagnetic HRP-
labelled beads, which massively amplified the current signals for a very low PSA detection

255 limit. A similar detection technique was improved and integrated in a microfluidic system by
256 Chikkaveeraiah et al. (2011) reaching an even lower detection limit. A fascinating
257 electrochemiluminescence-based immunoassay was developed by Sardesai et al. (2011) for
258 both PSA and interleukin 6 (IL-6) by using single-wall carbon nanotubes (SWCNT) fabricated
259 on microwells and a sandwich assay where the secondary PSA antibody was functionalized
260 with RuBYP-Silica particles: the detection limit achieved was of 1 pg/ml for PSA.

261

262 ***Label-free electrochemical sensors for PSA detection***

263 Electrochemical techniques are widely employed in biosensing devices as they can be
264 highly sensitive, simple to perform and cost effective. An electrochemical biosensor involves
265 an electrode surface that is functionalised with a molecular recognition element for sensing
266 biomolecules. Binding of an analyte to this element results in an electrical change in current
267 transfer (amperometric), voltage (potentiometric and field effect transistors), impedance
268 (impedimetric), conductivity (conductometric) or ion charge across the electrode, which can
269 be quantified and correlated to the amount of analyte captured. As mentioned in the previous
270 sections, most biosensors for PSA detection currently available are antibody-based. Amongst
271 the antibody-based electrochemical sensors, particularly important results are the ones using
272 label-free systems. Arya & Bhansali (2012) developed a gold biosensor modified with a
273 cysteamine self-assembled monolayer (SAM) for PSA detection. Li et al. (2005), on the hand,
274 employed In₂O₃ nanowires and carbon nanotubes. Electrochemical impedance spectroscopy
275 (EIS) based sensors have been reported by Chiriaco et al. (2013) and Chornokur et al. (2011).
276 The former exploits a combined use of two different antibodies for both free and total PSA,
277 while the latter reported on a miniaturized sensor obtained with photolithographic techniques
278 using a single monoclonal antibody. Another label-free antibody-based sensor which uses a
279 polycrystalline silicon field-effect transistor was reported by Huang et al. (2013).

280

281

282

Aptasensor for PSA detection

283

284 An aptasensor biosensor comprises an aptamer as a biorecognition element (Lim et al.,
285 2009). Aptasensors can be integrated with different sensing techniques such as
286 electrochemical, optical, and mass sensitive. Among these varied techniques, electrochemical
287 aptasensors have been fabricated using several detection techniques, namely EIS,
288 potentiometry and differential pulse voltammetry (DPV) (Cho et al., 2009; Clark & Remcho,

289 2002; Feng et al., 2008; Ikebukuro et al., 2005; Liu et al., 2012; Numnuam et al., 2008; Wang
 290 et al., 2007; Xu et al., 2005). For detection of PSA, both RNA and DNA aptamers have been
 291 developed, although there are only a handful of reports on PSA biosensors using aptamers. A
 292 summary of aptamer-based biosensors for PCa detection is presented in table 1.

293

294

295 **Table 1.** Performance comparison of different aptasensors for PCa detection

296

<i>Method</i>	<i>Material</i>	<i>Biomarker</i>	<i>Detection limit</i>	<i>Reference</i>
QCM-D/EIS	Gold	PSA	-	Formisano et al., 2014
EIS	Gold	PSA	1 ng/ml	Jolly et al., 2014
Optical	AuNPs	PSA	32 pg/ml	Chen et al., 2012
DPV/CV	AuNPs@GMCs	PSA	0.25 ng/ml	Liu et al., 2012
EIS	Gold	PSMA cells	-	Min et al., 2010

297

298

299 The first aptamer developed was a RNA aptamer (Jeong et al., 2010) that has been
 300 used to demonstrate the recognition of active PSA. Following that, a DNA aptamer was
 301 developed using a genetic algorithm with post-SELEX screening against PSA (Savory et al.,
 302 2010). To date, there is no reported literature on the application of RNA aptamers for PSA
 303 biosensing, which could be due to the long length of the sequence making it difficult to
 304 synthesise commercially.


305

DNA based PSA aptamer has been combined with different sensing techniques with
 306 sensitivities ranging from pg/ml to ng/ml. Chen et al. (2012) were the first to report the use of
 307 PSA aptamer to develop an optical based aptasensor. The conjugation of gold nanoparticles
 308 (AuNPs) with DNA aptamers were used to develop an aptasensor based on resonance light
 309 scattering (RLS) spectral assay. The novel technique relied on changes in resonance light
 310 scattering on binding of PSA to the aptamer, with a detection limit of 32 pg/ml. Thiolated
 311 DNA aptamers were immobilized on AuNPs and then a blocking step with BSA was
 312 performed prior the use of the complex AuNPs-aptamers with PSA samples. In this
 313 configuration, the gold surface of the nanoparticles was covered by the flexible aptamer
 314 structure and as a result no aggregation of particles occurred in absence of PSA. In the
 315 presence of PSA, aptamer-PSA complexes were formed and the aptamers undergo a
 316 conformational change in their structure from flexible to rigid. The changes in aptamer

317 conformation exposed some parts of the AuNPs that were thus available to form AuNPs
 318 aggregates upon addition of potassium chloride. This resulted in an increase in the RLS
 319 signal. The assay exhibited good sensitivity and selectivity towards PSA and tests made on
 320 human blood samples showed results comparable to those obtained with ELISA (relative
 321 deviation < 7%).

322

323



324

325

326 **Fig. 2.** Schematic illustration of fabrication process of the aptasensor based on gold
 327 nanoparticles encapsulated by graphitized mesoporous carbon (a); PSA detection (b).
 328 Adapted from Liu et al. (2012).

329

330


331 With regards to electrochemical aptasensor, modification of the electrode surface is
 332 one of the biggest fields of investigation. Research is typically focused on finding the most
 333 suitable recognition platform to give a stable organization to the sensor interface leading to
 334 optimized binding efficiency and signal outcome (Lee et al., 2005; Putzbach & Ronkainen,
 335 2013). Liu et al. (2012) applied aptasensors based on amplification via AuNPs and

336 graphitized mesoporous carbon (GMCs) combined with streptavidin-biotin system for
337 electrochemical detection of PSA (see fig. 2). GMCs encapsulated AuNPs formed the first
338 layer on cleaned pyrolytic graphite electrode followed by coating with streptavidin. All the
339 non-specific sites were blocked with bovine serum albumin (BSA). Finally, biotinylated DNA
340 aptamers were allowed to react with streptavidin immobilized on electrode surface. The
341 fabricated aptasensor was then used to capture PSA which was measured via differential pulse
342 voltammetry (DPV). The limit of detection of the aptasensor was 0.25 ng/ml with high
343 specificity to PSA. In spite of high sensitivity and specificity, the fabrication procedure which
344 is a layer-by-layer development of sensor surface is quite complex, which may be a drawback
345 in fabricating a cost effective sensor. The group also used Electrochemical Impedance
346 Spectroscopy (EIS) to characterize the layer-by-layer fabrication of the aptasensor.

347 Electrochemical Impedance Spectroscopy is one of the most promising
348 electrochemical techniques for DNA-based approaches but requires a careful design in order
349 to optimize its signal. Particularly important for EIS biosensors is the formation of a well-
350 organized self-assembled monolayer (SAM) which allows an optimal charge transfer to occur.
351 For successful EIS measurements, it is necessary to have a good and reliable SAM layer on
352 the gold electrode surface. One of the most accepted approaches to achieve this goal is by
353 alkanethiol chemistry. Alkanethiols can be easily adsorbed and form SAMs (Love et al.,
354 2005) on a clean gold surface through thiol bonds (see fig. 3). It has been reported that longer
355 alkane chains give a more compact structure with minimal defects (Campuzano et al., 2006).
356 Among different configuration of SAM, a mixed SAM of 11-Mercaptoundecanoic acid
357 (MUA), $\text{HS}(\text{CH}_2)_{10}\text{COOH}$, and 6-Mercapto-1-hexanol (MCH), $\text{HS}(\text{CH}_2)_6\text{OH}$, exhibited
358 reasonable starting impedance values and improved reliability (Herne & Tarlov, 1997). In
359 order to gather or to enhance the extent of a measurable signal of the recognition event
360 occurring on the working electrode, marker molecules such as redox couples, are exploited.
361 The recognition events that happen on the SAM not only modify the charge transfer processes
362 between redox couples present in the measurement solution and the sensor surface but also
363 affect the double layer at the sensor interface. Both these events cause a change in the system
364 charge transfer resistance (R_{ct}) which can then be measured by using an appropriate
365 equivalent circuit.

366

367



368

369

370 **Fig. 3.** Schematic illustration of fabrication process of the aptasensor with 6-mercaptohexanol
 371 and thiolated DNA aptamer.

372


373

374 In EIS measurements using PSA aptamers, Jolly et al. (2014) and Formisano et al.
 375 (2014) reported a reduction in charge transfer resistance (R_{ct}) upon binding of PSA to the
 376 immobilised DNA aptamers. This decrease is contradictory to what has been reported in the
 377 literature for PSA where an increase of R_{ct} has been observed (Liu et al., 2012), even though
 378 these studies used EIS mainly to characterize the bio-recognition layer and not for dose
 379 response determination. A reduction of R_{ct} upon aptamer-analyte interaction has also been
 380 reported for a different aptasensor using a lysozyme aptamer, where the reduction in charge
 381 transfer resistance upon binding of lysozyme to its specific DNA aptamer was attributed
 382 mainly due to screening of charges on DNA (Rodriguez et al., 2005). The reduction of R_{ct}
 383 could arise from two reasons: firstly, upon binding, PSA might screen the charges of the DNA
 384 aptamer; secondly, as PSA is also a charged protein, it could be that more positive charges are
 385 exposed because of the protein architecture itself. Consequently, as there is screening of
 386 charges of DNA, there is a reduction on electrostatic barrier to the ferro/ferricyanide anions
 387 towards the electrode surface, leading to lowering of the R_{ct} value of the system.

388 Earlier reports on DNA detection using DNA (Keighley et al., 2008a) and PNA probes
 389 (Keighley et al., 2008b) have demonstrated the importance of optimization of the
 390 oligonucleotide probe surface coverage in order to have efficient binding. On the same
 391 grounds, Formisano et al. (2014) investigated for the first time the importance of optimization
 392 of surface coverage by DNA aptamer for efficient binding using Quartz Crystal Microbalance


393 with Dissipation mode (QCM-D). The aim of this study was to optimize the conditions of an
394 EIS aptamer-based sensor for PSA detection. In fact, EIS optimisation for DNA aptamers is
395 somewhat complex due to the different characteristics that induce a signal change: namely
396 DNA density, change in charge density close to the electrode upon DNA conformational
397 changes, size and charge of the analyte, screening of DNA charges upon analyte binding. The
398 use of QCM-D provided valuable information about conditions for maximum analyte binding
399 as well as the hydration, folding and behaviour of the aptamer distribution on the electrode.
400 The system comprised a gold surface functionalized with a mixed SAM made of DNA
401 aptamer and MCH which was used as spacer molecule. The best conditions in terms of buffer
402 solution and aptamer mole fraction (concentration of aptamers/total thiols) for the binding of
403 PSA to the aptamers were obtained by comparing the data from two techniques under similar
404 conditions. With regards to the buffer conditions, the study demonstrated how the DNA
405 aptamers' behaviour exhibits a strong dependence on the environment where it interacts with
406 PSA.

407 In order to investigate an optimum surface chemistry that not only has a good
408 antifouling effect but is also simple and cost effective, a new molecule has been investigated
409 by Jolly et al. (2014) as a spacer molecule replacing MCH: a thiol terminated sulfo-betaine
410 (fig 4). It was the first report on thiol terminated sulfo-betaine application for aptamer-based
411 sensor. Thiol terminated sulfo-betaine, which has a molecular mass of 398.6 g/mole, is a
412 zwitter ion due to presence of both positive and negative charges with a flexible chain that
413 makes it a good antifouling molecule (see Fig 5). It been reported that sulfo-betaine not only
414 reduces non-specific binding but also increases the sensitivity of the sensor (Bertok et al.,
415 2013).



418
419
420 **Fig. 4.** Structure of thiol terminated sulfo-betaine. Image adapted from Bertok et al. (2013).

421
422



423

424

425 **Fig. 5.** Schematic of fabrication of thiol terminated sulfo-betaine based PSA aptasensor. (a)
 426 First SAM layer by co-immobilizing 11-mercaptoundecanoic acid with thiol terminated
 427 sulfo-betaine. Image adapted from Jolly et al. (2014).

428

429

430 A comparison study between MCH and thiol terminated sulfo-betaine thiol chemistry
 431 was carried out by monitoring non-specific binding using human serum albumin (HSA) as a
 432 control protein. A schematic of the fabrication protocol for surface chemistry with thiol
 433 terminated sulfo-betaine is presented in fig 5. Co-immobilization of 11-mercaptoundecanoic
 434 acid (MUA) and thiol terminated sulfo-betaine formed the first SAM layer on clean gold
 435 electrodes. The carboxyl group of MUA was then activated with conventional EDC/NHS
 436 coupling reaction. The activated carboxyl groups were then used to immobilize amine
 437 terminated DNA aptamers for PSA and finally the electrodes were treated with ethanolamine
 438 to deactivate all the unreacted groups. The fabricated aptasensor with thiol terminated sulfo-
 439 betaine surface chemistry can discriminate PSA levels down to 1 ng/ml, which falls in the

440 lower clinical cut-off range of PSA in blood. The fabricated aptasensor with thiol terminated
441 sulfo-betaine also showed a significant reduction of the non-specific binding with HSA as
442 compared to the sensor where MCH was used instead as a spacer molecule. However, it has
443 also been reported the obstacles on the optimization of the amount of DNA aptamers
444 immobilized on the surface via EDC/NHS coupling. It was assumed that the charged thiol
445 terminated sulfo-betaine has an influence on the attachment of DNA aptamer to activated
446 MUA via EDC/NHS coupling leading to difference in amounts of DNA aptamers in different
447 electrodes fabricated under similar conditions.

448

449

450

Aptasensors for other PCa biomarkers

451

452 Besides PSA, other biomarkers for PCa are currently studied and can potentially be
453 used for DNA/RNA-based detection systems. One is the prostate-specific membrane antigen
454 (PSMA), which is a type II integral membrane glycoprotein found in human serum. It is
455 overexpressed on prostate tumour cells and may play an important role in the progression of
456 PCa. It can also differentiate between BPH and PCa (Feneley et al., 2000; Ghosh and Heston,
457 2004; Madu and Lu, 2010; Pircher et al., 2011). Furthermore, by analysing the expression of
458 PSMA, two cell lines can be distinguished among PCa cells: PSMA (-) and PSMA (+) cells
459 (Ghosh and Heston, 2004). Min et al. (2010) reported on an RNA/peptide dual-aptamer-based
460 biosensor able to detect both PSMA (-) and PSMA (+) cells by using EIS. The biosensor
461 comprises of an anti-PSMA RNA aptamer (Lupold et al., 2002) which can target PSMA (+)
462 cells and a DUP-1 peptide aptamer (Zitzmann et al., 2005) specific for PSMA (-) cells.

463 Another emerging biomarker is Alpha-methylacyl-CoA Racemase (AMACR), which
464 is a racemase type of protein found in urine and blood. Its function is to metabolize fatty acids
465 in the human body. It is also overexpressed in PCa and can be detected with a high sensitivity
466 and specificity with a cut off value of 10.6 ng/ml. It also has the potential to differentiate
467 between BPH and PCa. Currently AMACR aptamers have been independently developed by
468 Base Pair Biotechnologies, Inc. (aptamer AM310_2) and by Yang et al. (2013). However, no
469 reports on their application to biosensing have been published so far.

470

471

472

Future perspectives and conclusions

473

474 Recent work on the development of PSA aptasensors has enabled the transition from
475 using antibody to aptamers as a recognition layer. Surface modification plays an important
476 role in the development of promising biosensors which would be aided with the ongoing
477 revolution in fabrication techniques. Easier fabrication would enable these biosensors to be
478 mass produced and commercially viable. The inclination towards the development of
479 aptasensors for PSA still needs further investigation for its use as an alternative to antibodies.
480 Also, the sensitivity of an aptasensor is most likely to be influenced not only by the surface
481 chemistry but also by the analytical method used for the detection of the target molecule, and
482 so far no aptasensors have yet been used in complex samples such as blood. Overall, the
483 development of aptamer based biosensor will see increasing reported literature because of its
484 ease of synthesis and the possibilities of multiple modifications; it will always be a fresh field
485 for more scope of adaptation of methodologies that will finally drive their solicitations with
486 real blood samples. For early diagnosis of PCa, detection of different biomarkers would be
487 preferred; consequently, more work is expected on development of aptamers for different
488 isoforms of PSA and other biomarkers of PCa. An ideal biosensor for PCa detection would be
489 based on a parallel sensing of different biomarkers using an array of sensors for more accurate
490 diagnosis. In addition to the need for a simple surface chemistry, the scope of biosensor in
491 future point-of-care devices will majorly depend on the integration of the format into a device
492 that will enable easy and simple sample handling and an efficient read out system with rapid
493 and accurate sample analysis of minimal blood sample volumes.

494

495

496 *Acknowledgement(s). This work was funded by the European Commission FP7*
497 *Programme through the Marie Curie Initial Training Network PROSENSE (grant no.*
498 *317420, 2012-2016).*

499

500

501

References

502

503 Acevedo, B., Perera, Y., Ruiz, M., Rojas, G., Benítez, J., Ayala, M., & Gaviñondo, J. (2002).
504 Development and validation of a quantitative ELISA for the measurement of PSA
505 concentration. *Clinica Chimica Acta*, 317(1), 55-63. DOI: 10.1016/S0009-8981(01)00749-5.

- 506 Albrecht, S., Brandl, H., Steinke, M., & Freidt, T. (1994). Chemiluminescent enzyme
507 immunoassay of prostate-specific antigen based on indoxyl phosphate substrate. *Clinical*
508 *Chemistry*, 40(10), 1970-1971.
- 509 Andriole, G. L., Crawford, E. D., Grubb III, R. L., Buys, S. S., Chia, D., Church, T. R.,
510 Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., Weissfeld, J. L., Yokochi, L. A.,
511 O'Brien, B., Clapp, J. D., Rathmell, J.M., Riley, T. L., Hayes, R. B., Kramer, B. S.,
512 Izmirlian, G., Miller, A. B., Pinsky, P. F., Prorok, P. C., Gohagan, J. K., & Berg, C. D.
513 (2009). Mortality results from a randomized prostate-cancer screening trial. *New England*
514 *Journal of Medicine*, 360(13), 1310-1319. DOI: 10.1056/NEJMoa0810696.
- 515 Arya, S. K., & Bhansali, S. (2012). Anti-prostate specific antigen (anti-PSA) modified
516 interdigitated microelectrode-based impedimetric biosensor for PSA detection. *Biosensors*
517 *Journal 1*, H110601. DOI: 10.4303/BJ/H110601.
- 518 Aus, G., Ahlgren, G., Bergdahl, S., & Hugosson, J. (1996). Infection after transrectal core
519 biopsies of the prostate. *British Journal of Urology*, 77(6), 851-855. DOI: 10.1046/j.1464-
520 410X.1996.01014.x.
- 521 Balducci, L., Pow-Sang, J., Friedland, J., & Diaz, J. I. (1997). Prostate cancer. *Clinics in*
522 *Geriatric Medicine*, 13(2), 283-306.
- 523 Balk, S. P., Ko, Y. J., & Bubley, G. J. (2003). Biology of prostate-specific antigen. *Journal of*
524 *Clinical Oncology*, 21(2), 383-391. DOI:10.1200/JCO.2003.02.083.
- 525 Basler, J. W., & Thompson, I. M. (1998). Lest we abandon digital rectal examination as a
526 screening test for prostate cancer. *Journal of the National Cancer Institute*, 90(23), 1761-
527 1763. DOI: 10.1093/jnci/90.23.1761.
- 528 Bertok, T., Klukova, L., Sediva, A., Kasák, P., Semak, V., Micusik, M., Omastova, M.,
529 Chovanová, L., Vlček, M., Imrich, R., Vikartovska, A., & Tkac, J. (2013). Ultrasensitive
530 impedimetric lectin biosensors with efficient antifouling properties applied in glycoprofiling
531 of human serum samples. *Analytical Chemistry*, 85(15), 7324-7332. DOI:
532 10.1021/ac401281t.
- 533 Besselink, G. A. J., Kooyman, R. P. H., van Os, P. J., Engbers, G. H., & Schasfoort, R. B.
534 (2004). Signal amplification on planar and gel-type sensor surfaces in surface plasmon
535 resonance-based detection of prostate-specific antigen. *Analytical Biochemistry*, 333(1), 165-
536 173. DOI: 10.1016/j.ab.2004.05.009.
- 537 Bostwick, D. G. (1989). The pathology of early prostate cancer. *CA: a Cancer Journal for*
538 *Clinicians*, 39(6), 376-393. DOI: 10.3322/canjclin.39.6.376.

- 539 Campuzano, S., Pedrero, M., Montemayor, C., Fatás, E., & Pingarrón, J. M. (2006).
540 Characterization of alkanethiol-self-assembled monolayers-modified gold electrodes by
541 electrochemical impedance spectroscopy. *Journal of Electroanalytical Chemistry*, 586(1),
542 112-121. DOI: 10.1016/j.jelechem.2005.09.007.
- 543 Cao, C., & Sim, S. J. (2007). Double-enhancement strategy: a practical approach to a femto-
544 molar level detection of prostate specific antigen-alpha1-antichymotrypsin (PSA/ACT
545 complex) for SPR immunosensing. *Journal of Microbiology and Biotechnology*, 17(6), 1031-
546 1035.
- 547 Carter, H. B., Pearson, J. D., Metter, E. J., Brant, L. J., Chan, D. W., Andres, R., Fozard J. L.,
548 & Walsh, P. C. (1992). Longitudinal evaluation of prostate-specific antigen levels in men
549 with and without prostate disease. *Journal of the American Medical Association*, 267(16),
550 2215.-2220. DOI: 10.1001/jama.267.16.2215.
- 551 Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. J.,
552 Petros, J. A., Andriole, G. L. (1991). Measurement of prostate-specific antigen in serum as a
553 screening test for prostate cancer. *New England Journal of Medicine*, 324(17), 1156-1161.
554 DOI: 10.1056/NEJM199104253241702.
- 555 Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A.,
556 Richie, J. P., deKernion J. B., Walsh, P. C., Scardino, P. T., Lange, P. H., Subong, E. N.,
557 Parson, R. E., Gasior, G. H., Loveland, K. G., Southwick, P. C. (1998). Use of the
558 percentage of free prostate-specific antigen to enhance differentiation of prostate cancer
559 from benign prostatic disease: a prospective multicenter clinical trial. *Journal of the*
560 *American Medical Association*, 279(19), 1542-1547. DOI: 10.1001/jama.279.19.1542.
- 561 Chen, Z., Lei, Y., Chen, X., Wang, Z., & Liu, J. (2012). An aptamer based resonance light
562 scattering assay of prostate specific antigen. *Biosensors and Bioelectronics*, 36(1), 35-40.
563 DOI: 10.1016/j.bios.2012.03.041.
- 564 Chikkaveeraiah, B. V.; Mani, V.; Patel, V.; Gutkind, J. S.; & Rusling, J. F. (2011).
565 Microfluidic electrochemical immunoarray for ultrasensitive detection of two cancer
566 biomarker proteins in serum. *Biosensors and Bioelectronics*, 26(11), 4477-4483. DOI:
567 10.1016/j.bios.2011.05.005.
- 568 Chiriaco, M. S., Primiceri, E., Montanaro, A., de Feo, F., Leone, L., Rinaldi, R., & Maruccio,
569 G. (2013). On-chip screening for prostate cancer: an EIS microfluidic platform for
570 contemporary detection of free and total PSA. *Analyst*, 138(18), 5404-5410. DOI:
571 10.1039/c3an00911d.

- 572 Cho, E. J., Lee, J. W., & Ellington, A. D. (2009). Applications of aptamers as sensors. *Annual*
573 *Review of Analytical Chemistry*, 2, 241-264. DOI:
574 10.1146/annurev.anchem.1.031207.112851.
- 575 Chornokur, G., Arya, S. K., Phelan, C., Tanner, R., & Bhansali, S. (2011). Impedance-based
576 miniaturized biosensor for ultrasensitive and fast prostate-specific antigen detection. *Journal*
577 *of Sensors*, 2011, 983752. DOI: 10.1155/2011/983752.
- 578 Chou, E., & Simons, J. W. (1997). The molecular biology of prostate cancer morbidity and
579 mortality: accelerated death from ejaculate poisoning? *Urologic Oncology: Seminars and*
580 *Original Investigations*, 3(3), 79-84. DOI: 10.1016/S1078-1439(97)00041-0.
- 581 Christensson, A. S., Björk, T., Nilsson, O., Dahlén, U., Matikainen, M. T., Cockett, A. T.,
582 Abrahamsson P. A., Lilja, H. (1993). Serum prostate specific antigen complexed to alpha 1-
583 antichymotrypsin as an indicator of prostate cancer. *Journal of Urology*, 150(1), 100.
- 584 Clark, S. L., & Remcho, V. T. (2002). Aptamers as analytical reagents. *Electrophoresis*,
585 23(9), 1335-1340. DOI: 10.1002/1522-2683(200205)23:9<1335::AID-ELPS1335>3.0.CO;2-
586 E.
- 587 D'Amico, A. V., Chen, M. H., Roehl, K. A., & Catalona, W. J. (2004). Preoperative PSA
588 velocity and the risk of death from prostate cancer after radical prostatectomy. *New England*
589 *Journal of Medicine*, 351(2), 125-135. DOI: 10.1056/NEJMoa032975.
- 590 D'Amico, A. V., Renshaw, A. A., Sussman, B., & Chen, M. H. (2005). Pretreatment PSA
591 velocity and risk of death from prostate cancer following external beam radiation therapy.
592 *Journal of the American Medical Association*, 294(4), 440-447. DOI:
593 10.1001/jama.294.4.440.
- 594 Feneley, M. R., Jan, H., Granowska, M., Mather, S. J., Ellison, D., Glass, J., Coptcoat, M.,
595 Kirby, R. S., Ogden, C., Oliver, R. T. D., Badenoch, D. F., Chinegwundoh, F. I., Nargund,
596 V. H., Paris, A. M. I., & Britton, K. E. (2000). Imaging with prostate-specific membrane
597 antigen (PSMA) in prostate cancer. *Prostate Cancer and Prostatic Diseases*, 3(1), 47-52.
598 DOI: 10.1038/sj.pcan.4500390.
- 599 Feng, K., Sun, C., Kang, Y., Chen, J., Jiang, J. H., Shen, G. L., & Yu, R. Q. (2008). Label-
600 free electrochemical detection of nanomolar adenosine based on target-induced aptamer
601 displacement. *Electrochemistry Communications*, 10(4), 531-535.
602 DOI:10.1016/j.elecom.2008.01.024.
- 603 Fernández-Sánchez, C., McNeil, C. J., Rawson, K., & Nilsson, O. (2004). Disposable
604 noncompetitive immunosensor for free and total prostate-specific antigen based on

- 605 capacitance measurement. *Analytical Chemistry*, 76(19), 5649-5656. DOI:
606 10.1021/ac0494937.
- 607 Formisano, N., Jolly, P., Cromhout, M., Fogel, R., Limson, J. L., & Estrela, P. (2014).
608 Optimisation of an electrochemical impedance spectroscopy aptasensor by exploiting quartz
609 crystal microbalance with dissipation signals. *Submitted for publication*.
- 610 Ghosh, A., & Heston, W. D. W. (2004). Tumor target prostate specific membrane antigen
611 (PSMA) and its regulation in prostate cancer. *Journal of Cellular Biochemistry*, 91(3), 528-
612 539. DOI: 10.1002/jcb.10661.
- 613 Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000). Cancer statistics, 2000. *CA: a*
614 *Cancer Journal for Clinicians*, 50(1), 7-33. DOI: 10.3322/canjclin.50.1.7.
- 615 Grossklaus, D. J., Smith Jr, J. A., Shappell, S. B., Coffey, C. S., Chang, S. S., & Cookson, M.
616 S. (2002). The free/total prostate-specific antigen ratio (% fPSA) is the best predictor of
617 tumor involvement in the radical prostatectomy specimen among men with an elevated PSA.
618 *Urologic Oncology: Seminars and Original Investigations*, 7(5), 195-198. DOI:
619 10.1016/S1078-1439(02)00190-4.
- 620 Healy, D. A., Hayes, C. J., Leonard, P., McKenna, L., & O'Kennedy, R. (2007). Biosensor
621 developments: application to prostate-specific antigen detection. *Trends in Biotechnology*,
622 25(3), 125-131. DOI: 10.1016/j.tibtech.2007.01.004.
- 623 Hermann, T., & Patel, D. J. (2000). Adaptive recognition by nucleic acid aptamers. *Science*,
624 287(5454), 820-825. DOI: 10.1126/science.287.5454.
- 625 Herne, T. M., & Tarlov, M. J. (1997). Characterization of DNA probes immobilized on gold
626 surfaces. *Journal of the American Chemical Society*, 119(38), 8916-8920. DOI:
627 10.1021/ja9719586.
- 628 Hianik, T., & Wang, J. (2009). Electrochemical aptasensors—recent achievements and
629 perspectives. *Electroanalysis*, 21(11), 1223-1235. DOI: 10.1002/elan.200904566.
- 630 Hoffman, R. M. (2011). Screening for prostate cancer. *New England Journal of Medicine*,
631 365(21), 2013-2019. DOI: 10.1056/NEJMcp1103642.
- 632 Huang, L., Reekmans, G., Saerens, D., Friedt, J. M., Frederix, F., Francis, L., Muyldermans,
633 S., Campitelli, A., & Van Hoof, C. (2005). Prostate-specific antigen immunosensing based
634 on mixed self-assembled monolayers, camel antibodies and colloidal gold enhanced
635 sandwich assays. *Biosensors and Bioelectronics*, 21(3), 483-490.
636 DOI:10.1016/j.bios.2004.11.016.
- 637 Huang, Y. W., Wu, C. S., Chuang, C. K., Pang, S. T., Pan, T. M., Yang, Y. S., & Ko, F. H.
638 (2013). Real-time and label-free detection of the prostate-specific antigen in human serum

- 639 by a polycrystalline silicon nanowire field-effect transistor biosensor. *Analytical Chemistry*,
640 85(16), 7912-7918. DOI: 10.1021/ac401610s.
- 641 Ikebukuro, K., Kiyohara, C., & Sode, K. (2005). Novel electrochemical sensor system for
642 protein using the aptamers in sandwich manner. *Biosensors and Bioelectronics*, 20(10),
643 2168-2172. DOI: 10.1016/j.bios.2004.09.002.
- 644 Iliuk, A. B., Hu, L., & Tao, W. A. (2011). Aptamer in bioanalytical applications. *Analytical*
645 *Chemistry*, 83(12), 4440-4452. DOI: 10.1021/ac201057w.
- 646 Irani, J., Fournier, F., Bon, D., Gremmo, E., Dore, B., & Aubert, J. (1997). Patient tolerance
647 of transrectal ultrasound-guided biopsy of the prostate. *British journal of urology*, 79(4),
648 608-610. DOI: 10.1046/j.1464-410X.1997.00120.x.
- 649 Jeong, S., Han, S. R., Lee, Y. J., & Lee, S. W. (2010). Selection of RNA aptamers specific to
650 active prostate-specific antigen. *Biotechnology letters*, 32(3), 379-385. DOI:
651 10.1007/s10529-009-0168-1.
- 652 Jiang, Z., Fanger, G. R., Woda, B. A., Banner, B. F., Algate, P., Dresser, K., Xu, J., & Chu, P.
653 G. (2003). Expression of α -methylacyl-CoA racemase (p504s) in various malignant
654 neoplasms and normal tissues: a study of 761 cases. *Human Pathology*, 34(8), 792-796.
655 DOI: 10.1016/S0046-8177(03)00268-5.
- 656 Jolly, P., Formisano, N., Tkáč, J., Kasák, P., Frost, C. G., & Estrela, P. (2014). Label-free
657 impedimetric prostate cancer aptasensor with antifouling surface chemistry. *Submitted for*
658 *publication*.
- 659 Keighley, S. D., Li, P., Estrela, P., & Migliorato, P. (2008a). Optimization of DNA
660 immobilization on gold electrodes for label-free detection by electrochemical impedance
661 spectroscopy. *Biosensors and Bioelectronics*, 23(8), 1291-1297. DOI:
662 10.1016/j.bios.2007.11.012.
- 663 Keighley, S. D., Estrela, P., Li, P., & Migliorato, P. (2008b). Optimization of label-free DNA
664 detection with electrochemical impedance spectroscopy using PNA probes. *Biosensors and*
665 *Bioelectronics*, 24(4), 906-911. DOI: 10.1016/j.bios.2008.07.041.
- 666 Kirk, D. (1997). MRC study: when to commence treatment in advanced prostate cancer.
667 *Prostate Cancer & Prostatic Diseases*, 1(1), 11-15.
- 668 Kufe, D. W., Pollock, R. E., Weichselbaum, R. R., Bast, R. C., & Gansler, T. S. (2003).
669 *Holland-Frei cancer medicine*: BC Decker Hamilton, ON.
- 670 Lee, J. W., Sim, S. J., Cho, S. M., & Lee, J. (2005). Characterization of a self-assembled
671 monolayer of thiol on a gold surface and the fabrication of a biosensor chip based on surface

- 672 plasmon resonance for detecting anti-GAD antibody. *Biosensors and Bioelectronics*, 20(7),
673 1422-1427. DOI: 10.1016/j.bios.2004.04.017.
- 674 Leman, E. S., & Getzenberg, R. H. (2009). Biomarkers for prostate cancer. *Journal of*
675 *Cellular Biochemistry*, 108(1), 3-9. DOI: 10.1002/jcb.22227.
- 676 Li, C., Curreli, M., Lin, H., Lei, B., Ishikawa, F. N., Datar, R., Cote, R. J., Thompson, M. E.,
677 & Zhou, C. (2005). Complementary detection of prostate-specific antigen using In₂O₃
678 nanowires and carbon nanotubes. *Journal of the American Chemical Society*, 127(36),
679 12484-12485. DOI: 10.1021/ja053761g.
- 680 Lilja, H., Oldbring, J., Rannevik, G., & Laurell, C. B. (1987). Seminal vesicle-secreted
681 proteins and their reactions during gelation and liquefaction of human semen. *Journal of*
682 *Clinical Investigation*, 80(2), 281. DOI: 10.1172/JCI113070.
- 683 Lilja, H., Ulmert, D., & Vickers, A. J. (2008). Prostate-specific antigen and prostate cancer:
684 prediction, detection and monitoring. *Nature Reviews Cancer*, 8(4), 268-278. DOI:
685 10.1038/nrc2351.
- 686 Lim, Y. C., Kouzani, A. Z., & Duan, W. (2009). Aptasensors design considerations
687 *Computational intelligence and intelligent systems* (pp. 118-127): Springer. DOI:
688 10.1007/978-3-642-04962-0_14.
- 689 Lin, J., & Ju, H. (2005). Electrochemical and chemiluminescent immunosensors for tumor
690 markers. *Biosensors and Bioelectronics*, 20(8), 1461-1470. DOI:
691 10.1016/j.bios.2004.05.008.
- 692 Liu, B., Lu, L., Hua, E., Jiang, S., & Xie, G. (2012). Detection of the human prostate-specific
693 antigen using an aptasensor with gold nanoparticles encapsulated by graphitized mesoporous
694 carbon. *Microchimica Acta*, 178(1-2), 163-170. DOI: 10.1007/s00604-012-0822-5.
- 695 Liu, J., Lu, C. Y., Zhou, H., Xu, J. J., Wang, Z. H., & Chen, H. Y. (2013). A dual-functional
696 electrochemical biosensor for the detection of prostate specific antigen and telomerase
697 activity. *Chemical Communications*, 49(59), 6602-6604. DOI: 10.1039/C3CC43532F.
- 698 Loeb, S., & Catalona, W. J. (2007). Prostate-specific antigen in clinical practice. *Cancer*
699 *Letters*, 249(1), 30-39. DOI: 10.1016/j.canlet.2006.12.022.
- 700 Loeb, S., Vellekoop, A., Ahmed, H. U., Catto, J., Emberton, M., Nam, R., Rosario, D. J., &
701 Lotan, Y. (2013). Systematic review of complications of prostate biopsy. *European Urology*
702 64(6), 876-92. DOI: 10.1016/j.eururo.2013.05.049.
- 703 Love, J. C., Estroff, L. A., Kriebel, J. K., Nuzzo, R. G., & Whitesides, G. M. (2005). Self-
704 assembled monolayers of thiolates on metals as a form of nanotechnology. *Chemical*
705 *Reviews*, 105(4), 1103-1170. DOI:10.1021/cr0300789.

- 706 Lövgren, J., Valtonen-André, C., Marsal, K., Liua, H., & Lundwall, Å. (1999). Measurement
707 of prostate-specific antigen and human glandular kallikrein 2 in different body fluids.
708 *Journal of Andrology*, *20*(3), 348-355. DOI: 10.1002/j.1939-4640.1999.tb02528.x.
- 709 Lupold, S. E., Hicke, B. J., Lin, Y., & Coffey, D. S. (2002). Identification and characterization
710 of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-
711 specific membrane antigen. *Cancer Research*, *62*, 4029-4033.
- 712 Madu, C. O., & Lu, Y. (2010). Novel diagnostic biomarkers for prostate cancer. *Journal of*
713 *Cancer*, *1*, 150-177. DOI: 10.7150/jca.1.150.
- 714 Mairal, T., Özalp, V. C., Lozano Sánchez, P., Mir, M., Katakis, I., & O'Sullivan, C. K.
715 (2008). Aptamers: molecular tools for analytical applications. *Analytical and Bioanalytical*
716 *Chemistry*, *390*(4), 989-1007. DOI: 10.1007/s00216-007-1346-4.
- 717 Mani, V., Chikkaveeraiah, B. V., Patel, V., Gutkind, J. S., & Rusling, J. F. (2009).
718 Ultrasensitive immunosensor for cancer biomarker proteins using gold nanoparticle film
719 electrodes and multienzyme-particle amplification. *ACS Nano*, *3*(3), 585-594. DOI:
720 10.1021/nn800863w.
- 721 Maraldo, D., Garcia, F. U., & Mutharasan, R. (2007). Method for quantification of a prostate
722 cancer biomarker in urine without sample preparation. *Analytical Chemistry*, *79*(20), 7683-
723 7690. DOI: 10.1021/ac070895z.
- 724 Melichar, B. (2012). Tumor biomarkers: PSA and beyond. *Clinical Chemistry and*
725 *Laboratory Medicine*, *50*(11), 1865-1869. DOI: 10.1515/cclm-2012-0631.
- 726 Mikolajczyk, S. D., Marker, K. M., Millar, L. S., Kumar, A., Saedi, M. S., Payne, J. K.,
727 Evans, C. L., Gasoir, C. L., Linton, H. J., Carpenter, P., & Rittenhouse, H. G. (2001). A
728 truncated precursor form of prostate-specific antigen is a more specific serum marker of
729 prostate cancer. *Cancer Research*, *61*(18), 6958-6963.
- 730 Mikolajczyk, S. D., Catalona, W. J., Evans, C. L., Linton, H. J., Millar, L. S., Marker, K. M.,
731 Katir, D., Amirkhan, A., & Rittenhouse, H. G. (2004). Proenzyme forms of prostate-specific
732 antigen in serum improve the detection of prostate cancer. *Clinical Chemistry*, *50*(6), 1017-
733 1025. DOI: 10.1373/clinchem.2003.026823.
- 734 Min, K., Song, K. M., Cho, M., Chun, Y. S., Shim, Y. B., Ku, J. K., & Ban, C. (2010).
735 Simultaneous electrochemical detection of both PSMA (+) and PSMA (-) prostate cancer
736 cells using an RNA/peptide dual-aptamer probe. *Chemical Communications*, *46*, 5566-
737 5568. DOI: 10.1039/c002524k.

- 738 Moyer, V. A. (2012). Screening for prostate cancer: US Preventive Services Task Force
739 recommendation statement. *Annals of internal medicine*, *157*(2), 120-134. DOI:
740 10.7326/0003-4819-157-2-201207170-00459.
- 741 Numnuam, A., Chumbimuni-Torres, K. Y., Xiang, Y., Bash, R., Thavarungkul, P.,
742 Kanatharana, P., Pretsch, E., Wang, J., & Bakker, E. (2008). Aptamer-based potentiometric
743 measurements of proteins using ion-selective microelectrodes. *Analytical Chemistry*, *80*(3),
744 707-712. DOI: 10.1021/ac701910r.
- 745 Ohori, M., Dunn, J. K., & Scardino, P. T. (1995). Is prostate-specific antigen density more
746 useful than prostate-specific antigen levels in the diagnosis of prostate-cancer? *Urology*,
747 *46*(5), 666-671. DOI: 10.1016/s0090-4295(99)80298-2.
- 748 Okuno, J., Maehashi, K., Kerman, K., Takamura, Y., Matsumoto, K., & Tamiya, E. (2007).
749 Label-free immunosensor for prostate-specific antigen based on single-walled carbon
750 nanotube array-modified microelectrodes. *Biosensors and Bioelectronics*, *22*(9-10), 2377-
751 2381. DOI: 10.1016/j.bios.2006.09.038.
- 752 Panini, N. V., Messina, G. A., Salinas, E., Fernández, H., & Raba, J. (2008). Integrated
753 microfluidic systems with an immunosensor modified with carbon nanotubes for detection
754 of prostate specific antigen (PSA) in human serum samples. *Biosensors and Bioelectronics*,
755 *23*(7), 1145-1151. DOI: 10.1016/j.bios.2007.11.003.
- 756 Pinsky, P. F., Andriole, G., Crawford, E. D., Chia, D., Kramer, B. S., Grubb, R., Greenlee, R.,
757 & Gohagan, J. K. (2007). Prostate-specific antigen velocity and prostate cancer gleason
758 grade and stage. *Cancer*, *109*(8), 1689-1695. DOI: 10.1002/cncr.22558.
- 759 Pircher, A., Hilbe, W., Heidegger, I., Drevs, J., Tichelli, A., & Medinger, M. (2011).
760 Biomarkers in tumor angiogenesis and anti-angiogenic therapy. *International Journal of*
761 *Molecular Sciences*, *12*(10), 7077-7099. DOI: 10.3390/ijms12107077.
- 762 Putzbach, W., & Ronkainen, N. J. (2013). Immobilization techniques in the fabrication of
763 nanomaterial-based electrochemical biosensors: a review. *Sensors*, *13*(4), 4811-4840.
764 DOI:10.3390/s130404811.
- 765 Rodriguez, M. C., Kawde, A. N., & Wang, J. (2005). Aptamer biosensor for label-free
766 impedance spectroscopy detection of proteins based on recognition-induced switching of the
767 surface charge. *Chemical Communications*, (34), 4267-4269. DOI: 10.1039/B506571B.
- 768 Ross, R. K., Pike, M. C., Coetzee, G. A., Reichardt, J. K. V., Yu, M. C., Feigelson, H.,
769 Stanczyk, F. Z., Kolonel, L. N., & Henderson, B. E. (1998). Androgen metabolism and
770 prostate cancer: establishing a model of genetic susceptibility. *Cancer Research*, *58*(20),
771 4497-4504.

- 772 Rubin, M. A., Zhou, M., Dhanasekaran, S. M., Varambally, S., Barrette, T. R., Sanda, M. G.,
773 Pienta, K. J., Ghosh, D., & Chinnaiyan, A. M. (2002). α -methylacyl coenzyme A racemase
774 as a tissue biomarker for prostate cancer. *Journal of the American Medical Association*,
775 287(13), 1662-1670. DOI: 10.1001/jama.287.13.1662.
- 776 Sardesai, N. P., Barron, J. C., & Rusling, J. F. (2011). *Analytical Chemistry*, 83(17), 6698-
777 6703. DOI: 10.1021/ac201292q.
- 778 Sarkar, P., Pal, P. S., Ghosh, D., Setford, S. J., & Tothill, I. E. (2002). Amperometric
779 biosensors for detection of the prostate cancer marker (PSA). *International Journal of*
780 *Pharmaceutics*, 238(1), 1-9. DOI: 10.1016/S0378-5173(02)00015-7.
- 781 Savory, N., Abe, K., Sode, K., & Ikebukuro, K. (2010). Selection of DNA aptamer against
782 prostate specific antigen using a genetic algorithm and application to sensing. *Biosensors*
783 *and Bioelectronics*, 26(4), 1386-1391. DOI: 10.1016/j.bios.2010.07.057.
- 784 Seto, Y., Iba, T., & Abe, K. (2001). Development of ultra-high sensitivity bioluminescent
785 enzyme immunoassay for prostate-specific antigen (PSA) using firefly luciferase.
786 *Luminescence*, 16(4), 285-290. DOI: 10.1002/bio.654.
- 787 Song, S., Wang, L., Li, J., Fan, C., & Zhao, J. (2008). Aptamer-based biosensors. *Trends in*
788 *Analytical Chemistry*, 27(2), 108-117. DOI: 10.1016/j.trac.2007.12.004.
- 789 Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., & Redwine, E. (1987).
790 Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. *New*
791 *England Journal of Medicine*, 317(15), 909-916. DOI: 10.1056/nejm198710083171501.
- 792 Stanford, J. L., Stephenson, R. A., Coyle, L. M., Cerhan, J., Correa, R., Eley, J. W., Gilliland,
793 F., Hankey, B., Kolonel, L. N., Kosary, C., Ross, R., Severson, R., & West, D. (1999).
794 Prostate cancer trends 1973-1995, SEER Program, National Cancer Institute. *NIH pub 99-*
795 4543.
- 796 Stephan, C., Lein, M., Jung, K., Schnorr, D., & Loening, S. A. (1997). The influence of
797 prostate volume on the ratio of free to total prostate specific antigen in serum of patients
798 with prostate carcinoma and benign prostate hyperplasia. *Cancer*, 79(1), 104-109. DOI:
799 10.1002/(SICI)1097-0142(19970101)79:1<104::AID-CNCR15>3.0.CO;2-8.
- 800 Syed, M. A., & Pervaiz, S. (2010). Advances in aptamers. *Oligonucleotides*, 20(5), 215-224.
801 DOI: 10.1089/oli.2010.0234.
- 802 Takayama, T. K., Fujikawa, K., & Davie, E. W. (1997). Characterization of the precursor of
803 prostate-specific antigen Activation by trypsin and by human glandular kallikrein. *Journal of*
804 *Biological Chemistry*, 272(34), 21582-21588. DOI: 10.1074/jbc.272.34.21582.

- 805 Tombelli, S., Minunni, M., & Mascini, M. (2005). Analytical applications of aptamers.
806 *Biosensors and Bioelectronics*, 20(12), 2424-2434. DOI: 10.1016/j.bios.2004.11.006.
- 807 Uzzo, R. G., Wei, J. T., Waldbaum, R. S., Perlmutter, A. P., Byrne, J. C., & Vaughan Jr., D.
808 (1995). The influence of prostate size on cancer detection. *Urology*, 46(6), 831-836. DOI:
809 10.1016/S0090-4295(99)80353-7.
- 810 Velonas, V. M., Woo, H. H., dos Remedios, C. G., & Assinder, S. J. (2013). Current status of
811 biomarkers for prostate cancer. *International Journal of Molecular Sciences*, 14(6), 11034-
812 11060. DOI: 10.3390/ijms140611034.
- 813 Wang, X., Zhou, J., Yun, W., Xiao, S., Chang, Z., He, P., & Fang, Y. (2007). Detection of
814 thrombin using electrogenerated chemiluminescence based on Ru (bpy)₃²⁺-doped silica
815 nanoparticle aptasensor via target protein-induced strand displacement. *Analytica Chimica*
816 *Acta*, 598(2), 242-248. DOI: 10.1016/j.aca.2007.07.050.
- 817 Wee, K. W., Kang, G. Y., Park, J., Kang, J. Y., Yoon, D. S., Park, J. H., & Kim, T. S. (2005).
818 Novel electrical detection of label-free disease marker proteins using piezoresistive self-
819 sensing micro-cantilevers. *Biosensors and Bioelectronics*, 20(10), 1932-1938. DOI:
820 10.1016/j.bios.2004.09.023.
- 821 Weeks, B. L., Camarero, J., Noy, A., Miller, A. E., De Yoreo, J. J., & Stanker, L. (2003). A
822 microcantilever-based pathogen detector. *Scanning*, 25(6), 297-299. DOI:
823 10.1002/sca.4950250605.
- 824 Wu, C. L., Yang, X. J., Tretiakova, M., Patton, K. T., Halpern, E. F., Woda, B. A., Young, R.
825 H., & Jiang, Z. (2004). Analysis of α -methylacyl-CoA racemase (P504S) expression in high-
826 grade prostatic intraepithelial neoplasia. *Human Pathology*, 35(8), 1008-1013, 8. DOI:
827 10.1016/j.humpath.2004.03.019.
- 828 Willner, I., & Zayats, M. (2007). Electronic aptamer-based sensors. *Angewandte Chemie -*
829 *International Edition*, 46(34), 6408-6418. DOI: 10.1002/anie.200604524.
- 830 Xiao, Y., Lubin, A. A., Heeger, A. J., & Plaxco, K. W. (2005). Label-free electronic detection
831 of thrombin in blood serum by using an aptamer-based sensor. *Angewandte Chemie*,
832 117(34), 5592-5595. DOI: 10.1002/ange.200500989.
- 833 Xu, D., Xu, D., Yu, X., Liu, Z., He, W., & Ma, Z. (2005). Label-free electrochemical
834 detection for aptamer-based array electrodes. *Analytical Chemistry*, 77(16), 5107-5113. DOI:
835 10.1021/ac050192m.
- 836 Yang, D. K., Chen, C. S., & Chen, L. C. (2013). Screening of functional aptamers against
837 α -methylacyl-coA racemase. In Abstracts of the 13th American Institute of Chemical

838 Engineers Annual Meeting, November 3–8, 2013. Retrieved May 9, 2014, from
839 <https://aiche.confex.com/aiche/2013/webprogram/Paper332288.html>.

840 Zani, A.; Laschi, S.; Mascini, M.; & Marrazza, G. (2011). A new electrochemical multiplexed
841 assay for PSA cancer marker detection. *Electroanalysis*, 23(1), 91-99. DOI:
842 10.1002/elan.201000486.

843 Zitzmann, S., Mier, W., Schad, A., Kinscherf, R., Askozyllakis, V., Krämer, S., Altmann, A.,
844 Eisenhut, M., & Haberkorn, U. (2005). A new prostate carcinoma binding peptide (DUP-1)
845 for tumor imaging and therapy. *Clinical Cancer Research*, 11, 139-146.

846